AZILSIGN-CT Tablet by Dr Precision is a clinically formulated fixed-dose combination medication combining Azilsartan Medoxomil and Chlorthalidone for effective management of hypertension. Azilsartan Medoxomil, an angiotensin II receptor blocker (ARB), selectively targets AT1 receptors, promoting vasodilation and sustained 24-hour blood pressure control. Chlorthalidone, a long-acting thiazide-like diuretic, complements this action by inhibiting sodium and chloride reabsorption in the kidneys, aiding substantial plasma volume reduction. This potent dual mechanism results in superior antihypertensive efficacy, optimized for patients requiring dual therapy or those unresponsive to monotherapy. Manufactured under the stringent GMP-compliant protocols of Dr Precision, AZILSIGN-CT Tablets ensure high-quality, stable, and compliant treatment with convenient once-daily dosing in film-coated tablet form. Available in multiple strengths (Azilsartan 40 mg/80 mg and Chlorthalidone 12.5 mg/25 mg), the product caters to patient-specific therapeutic needs. AZILSIGN-CT effectively lowers cardiovascular risks by reducing stroke, myocardial infarction, and kidney complications, making it an indispensable choice for healthcare providers managing chronic hypertension, particularly in patients with salt sensitivity, fluid overload, or diabetes mellitus. The formulation also enhances patient adherence, reducing the morning surge in blood pressure and minimizing edema risks compared to calcium channel blockers.
Key Features
| Features | Description |
|---|---|
| Active Ingredients | Azilsartan Medoxomil (40 mg or 80 mg) and Chlorthalidone (12.5 mg or 25 mg) |
| Mechanism of Action | Selective AT1 receptor blocker (Azilsartan) and long-acting thiazide-like diuretic (Chlorthalidone) |
| Dosage Form | Film-coated tablet for enhanced stability and compliance |
| Indications | Treatment of essential hypertension and resistant hypertension |
| Therapeutic Benefits | Superior 24-hour blood pressure control and reduction of cardiovascular risks |
| Manufacturing Standards | GMP-compliant formulation under Dr Precision brand |
| Dosing Frequency | Once daily oral administration |
| Patient Suitability | Ideal for adults needing dual antihypertensive therapy or with salt sensitivity and coexisting conditions |
| Edema Incidence | Lower incidence compared to calcium channel blockers |
| Cardiovascular and Kidney Protection | Reduces the risk of stroke, myocardial infarction and kidney complications |
| Attributes | Description |
|---|---|
| Azilsartan Medoxomil Strength | 40 mg or 80 mg |
| Chlorthalidone Strength | 12.5 mg or 25 mg |
| Tablet Coating | Film-coated |
| Packaging | Available in blister packs or bottles (specific packing varies) |
| Storage Conditions | Store in a cool, dry place below 30°C, protect from moisture |
| Shelf Life | Typically 24 months from manufacturing date |
| Pharmacokinetics | Provides sustained 24-hour antihypertensive effect |
| Regulatory Compliance | Manufactured under GMP-certified facilities |
| Therapeutic Classification | Antihypertensive agent, combination ARB and diuretic |
| Intended Patient Type | Adults with essential or resistant hypertension |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
By combining Azilsartan Medoxomil and Chlorthalidone in a single once-daily tablet, AZILSIGN-CT eliminates the need for multiple medications, simplifying the regimen and improving patient compliance.
AZILSIGN-CT utilizes a dual mechanism where Azilsartan promotes vasodilation by blocking AT1 receptors and Chlorthalidone reduces plasma volume via diuretic action, addressing multiple pathways in blood pressure regulation for superior control.
Yes, AZILSIGN-CT is especially beneficial for patients with diabetes mellitus as it not only controls blood pressure but also provides kidney protection and reduces cardiovascular risk.
The tablets are available in Azilsartan Medoxomil strengths of 40 mg and 80 mg combined with Chlorthalidone 12.5 mg and 25 mg, allowing healthcare providers to titrate doses based on the severity of hypertension and patient response.
The sustained 24-hour antihypertensive effect of Azilsartan combined with the long-acting nature of Chlorthalidone minimizes the morning surge in blood pressure, thereby reducing peak cardiovascular risk times.
Country Of Origin: India
AZILSIGN-CT Tablet is a fixed-dose combination medication containing Azilsartan Medoxomil and Chlorthalidone, primarily used for the treatment of hypertension (high blood pressure). Azilsartan is an angiotensin II receptor blocker (ARB) that helps relax blood vessels, while Chlorthalidone is a long-acting thiazide-like diuretic that reduces excess fluid in the body. Together, they effectively lower blood pressure, reduce the risk of cardiovascular complications, and promote better heart and kidney health. AZILSIGN-CT Tablet is manufactured under stringent quality protocols, making it a reliable solution for managing chronic hypertension in adult patients.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
1. Product Overview
AZILSIGN-CT Tablet is a combination antihypertensive medication that integrates two powerful agents: Azilsartan Medoxomil (an ARB) and Chlorthalidone (a thiazide-like diuretic).
It is designed for once-daily oral administration and is especially suitable for patients who require dual therapy for effective blood pressure control.
The combination provides synergistic effects—Azilsartan relaxes vascular smooth muscle, and Chlorthalidone decreases plasma volume—leading to optimal antihypertensive outcomes.
2. Composition and Strengths
Active Ingredients:
Azilsartan Medoxomil: Typically 40 mg or 80 mg
Chlorthalidone: Typically 12.5 mg or 25 mg
Formulated in film-coated tablet form to enhance patient compliance and stability.
Available in various strengths to suit titration needs and patient-specific therapy.
3. Mechanism of Action
Azilsartan Medoxomil:
A selective angiotensin II receptor type 1 (AT1) blocker, it prevents angiotensin II from binding to AT1 receptors.
Results in vasodilation, reduced aldosterone secretion, and lower blood pressure.
Has high affinity for the AT1 receptor and offers sustained 24-hour blood pressure control.
Chlorthalidone:
A long-acting diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule of the nephron.
Leads to increased excretion of sodium, chloride, and water, thereby reducing plasma volume.
Also has mild vasodilatory effects and contributes to long-term cardiovascular protection.
4. Therapeutic Uses
Indicated for the treatment of essential hypertension in adults.
Used in patients who do not achieve adequate control with monotherapy.
May reduce the risk of stroke, myocardial infarction, heart failure, and kidney complications.
Especially beneficial in patients with salt sensitivity, fluid overload, or coexisting diabetes mellitus.
5. Clinical Benefits
Provides superior 24-hour blood pressure reduction compared to ARBs alone.
Helps in managing resistant hypertension where monotherapy is ineffective.
Reduces morning surge in blood pressure, which is associated with higher cardiovascular risk.
Improves patient adherence by offering two medications in a single, once-daily tablet.
Lower incidence of edema compared to calcium channel blockers.
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
